Seres Therapeutics Inc MCRB

NAS: MCRB | ISIN: US81750R1023 1/05/2024

1,080 USD (+9,02%)

(+9,02%) 1/05/2024

Grafiek Seres Therapeutics Inc

Grafiek Seres Therapeutics Inc

1 dag1d 9,02%
1 week1w 45,42%
1 maand1m 41,58%
3 maanden3m -1,82%
6 maanden6m 15,83%
1 jaar1j -76,87%
5 jaar5j -79,81%

Seres Therapeutics Inc in het nieuws

Toon enkel gratis nieuws

1 november 2023 · Flagship Pioneering Launches Pioneering Intelligence · Persbericht

11 september 2023 · Flagship Pioneering Announces Appointment of Amanda Kay as Chief Business Development Officer · Persbericht

29 augustus 2023 · Invaio achieves first registration for citrus greening solution featuring Trecise™ technology · Persbericht

16 mei 2023 · Flagship Pioneering Launches Metaphore Biotechnologies to Unlock the Therapeutic Potential of Biomimicry · Persbericht

28 februari 2022 · Alltrna Appoints Rare Disease Clinical Research Expert, Dr. Anne Pariser, as Vice President, Medical and Regulatory Affairs · Persbericht

15 februari 2022 · Invaio Sciences Strengthens Its Board Of Directors With The Appointment Of Hugh Grant · Persbericht

13 oktober 2021 · Invaio Sciences Secures $50 Million Debt Financing to Develop and Commercialize Agricultural Solutions to Address Climate Change · Persbericht

15 juni 2021 · Dr. Stephen Hahn, 24th US FDA Commissioner and Former Chief Medical Executive at MD Anderson, joins Flagship Pioneering as Chief Medical Officer of Flagship's Preemptive Medicine and Health Security Initiative · Persbericht

25 mei 2021 · Invaio Sciences Raises $88.9 Million to Accelerate the Transition to Biological Agriculture · Persbericht

19 mei 2021 · Invaio Sciences Announces Key Agreement with Fundecitrus in Brazil to Combat Against Citrus Greening · Persbericht

Profiel Seres Therapeutics Inc

Fabricage van farmaceutische preparaten

Gezondheidstechnologie

Website: serestherapeutics.com

Hoofdzetel: Cambridge, Massachusetts Verenigde Staten

CEO: Eric Shaff

Werknemers: 486

Aandelen Seres Therapeutics Inc

Beurswaarde: 149,59 miljoen USD

Effecten: 151,01 miljoen

Winst per aandeel (12 maand): PLUS

Beta: 1,01

Mijn selecties

Je selectie is nog leeg.

Voeg nu effecten toe